Spain · Delayed Price · Currency is EUR Pharma Mar Statistics
Total Valuation
Pharma Mar has a market cap or net worth of EUR 1.49 billion. The enterprise value is 1.37 billion.
| Market Cap | 1.49B |
| Enterprise Value | 1.37B |
Important Dates
The next estimated earnings date is Friday, April 24, 2026.
| Earnings Date | Apr 24, 2026 |
| Ex-Dividend Date | Jun 25, 2025 |
Share Statistics
Pharma Mar has 17.36 million shares outstanding. The number of shares has decreased by -0.62% in one year.
| Current Share Class | 17.36M |
| Shares Outstanding | 17.36M |
| Shares Change (YoY) | -0.62% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.01% |
| Owned by Institutions (%) | 9.92% |
| Float | 13.43M |
Valuation Ratios
The trailing PE ratio is 19.91 and the forward PE ratio is 33.93. Pharma Mar's PEG ratio is 0.44.
| PE Ratio | 19.91 |
| Forward PE | 33.93 |
| PS Ratio | 6.71 |
| PB Ratio | 5.90 |
| P/TBV Ratio | 5.93 |
| P/FCF Ratio | 31.84 |
| P/OCF Ratio | 27.97 |
| PEG Ratio | 0.44 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.01, with an EV/FCF ratio of 29.32.
| EV / Earnings | 18.25 |
| EV / Sales | 6.18 |
| EV / EBITDA | 20.01 |
| EV / EBIT | 22.54 |
| EV / FCF | 29.32 |
Financial Position
The company has a current ratio of 3.02, with a Debt / Equity ratio of 0.20.
| Current Ratio | 3.02 |
| Quick Ratio | 2.20 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 0.72 |
| Debt / FCF | 1.06 |
| Interest Coverage | 24.69 |
Financial Efficiency
Return on equity (ROE) is 32.59% and return on invested capital (ROIC) is 51.63%.
| Return on Equity (ROE) | 32.59% |
| Return on Assets (ROA) | 10.19% |
| Return on Invested Capital (ROIC) | 51.63% |
| Return on Capital Employed (ROCE) | 20.16% |
| Weighted Average Cost of Capital (WACC) | 5.95% |
| Revenue Per Employee | 438,396 |
| Profits Per Employee | 148,487 |
| Employee Count | 505 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 0.24 |
Taxes
| Income Tax | -15.34M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.38% in the last 52 weeks. The beta is 0.32, so Pharma Mar's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +13.38% |
| 50-Day Moving Average | 81.30 |
| 200-Day Moving Average | 80.49 |
| Relative Strength Index (RSI) | 51.30 |
| Average Volume (20 Days) | 71,935 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharma Mar had revenue of EUR 221.39 million and earned 74.99 million in profits. Earnings per share was 4.30.
| Revenue | 221.39M |
| Gross Profit | 209.13M |
| Operating Income | 60.72M |
| Pretax Income | 59.65M |
| Net Income | 74.99M |
| EBITDA | 66.47M |
| EBIT | 60.72M |
| Earnings Per Share (EPS) | 4.30 |
Balance Sheet
The company has 167.22 million in cash and 49.42 million in debt, with a net cash position of 117.81 million or 6.79 per share.
| Cash & Cash Equivalents | 167.22M |
| Total Debt | 49.42M |
| Net Cash | 117.81M |
| Net Cash Per Share | 6.79 |
| Equity (Book Value) | 251.83M |
| Book Value Per Share | 14.51 |
| Working Capital | 189.54M |
Cash Flow
In the last 12 months, operating cash flow was 53.13 million and capital expenditures -6.46 million, giving a free cash flow of 46.67 million.
| Operating Cash Flow | 53.13M |
| Capital Expenditures | -6.46M |
| Depreciation & Amortization | 5.75M |
| Net Borrowing | -4.33M |
| Free Cash Flow | 46.67M |
| FCF Per Share | 2.69 |
Margins
Gross margin is 94.46%, with operating and profit margins of 27.42% and 33.87%.
| Gross Margin | 94.46% |
| Operating Margin | 27.42% |
| Pretax Margin | 26.94% |
| Profit Margin | 33.87% |
| EBITDA Margin | 30.02% |
| EBIT Margin | 27.42% |
| FCF Margin | 21.08% |
Dividends & Yields
This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 0.88%.
| Dividend Per Share | 0.80 |
| Dividend Yield | 0.88% |
| Dividend Growth (YoY) | 23.08% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 18.60% |
| Buyback Yield | 0.62% |
| Shareholder Yield | 1.50% |
| Earnings Yield | 5.05% |
| FCF Yield | 3.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 22, 2020. It was a reverse split with a ratio of 0.0833333333.
| Last Split Date | Jul 22, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.0833333333 |
Scores
Pharma Mar has an Altman Z-Score of 8.47 and a Piotroski F-Score of 5.
| Altman Z-Score | 8.47 |
| Piotroski F-Score | 5 |